Related Experiment Video

Updated: Jan 15, 2026

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

22.3K

NCCN Guidelines® Insights: B-Cell Lymphomas 3.2025

Andrew D Zelenetz1, Leo I Gordon2, Jeremy S Abramson3

  • 11Memorial Sloan Kettering Cancer Center.

Journal of the National Comprehensive Cancer Network : JNCCN
|October 9, 2025
PubMed

Insights

Novel targeted therapies, including bispecific antibodies and Bruton tyrosine kinase (BTK) inhibitors, are transforming B-cell lymphoma treatment. These advancements show promise for follicular lymphoma (FL), mantle cell lymphoma (MCL), and diffuse large B-cell lymphoma (DLBCL).

Area of Science:

  • Hematology and Oncology
  • Clinical Therapeutics
  • Immunotherapy

Background:

  • The treatment of B-cell lymphomas has seen significant advancements with the recent approval of novel targeted therapies.
  • Established treatment protocols are being re-evaluated in light of emerging therapeutic options.

Purpose of the Study:

  • To highlight significant updates to the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas.
  • To review the efficacy of novel targeted therapies in specific B-cell lymphoma subtypes, including follicular lymphoma (FL), mantle cell lymphoma (MCL), and diffuse large B-cell lymphoma (DLBCL).

Main Methods:

  • Review of recent clinical trial data and regulatory approvals for targeted therapies in B-cell lymphomas.
  • Analysis of NCCN Guidelines updates pertaining to FL, MCL, and DLBCL treatment strategies.
  • Focus on CD3 × CD20 bispecific antibodies, CD19-directed monoclonal antibodies, antibody-drug conjugates, and Bruton tyrosine kinase (BTK) inhibitors.

Main Results:

  • CD3 × CD20 bispecific antibodies and CD19-directed therapies demonstrate efficacy in relapsed/refractory follicular lymphoma (FL).
  • Bruton tyrosine kinase (BTK) inhibitor-based regimens show effectiveness in TP53-mutated classical mantle cell lymphoma (MCL).
  • Addition of CD3 × CD20 bispecific antibodies to chemoimmunotherapy may improve outcomes in relapsed/refractory diffuse large B-cell lymphoma (DLBCL).

Conclusions:

  • Novel targeted therapies represent a paradigm shift in managing B-cell lymphomas.
  • Updated NCCN Guidelines reflect the integration of these new agents for FL, MCL, and DLBCL.
  • Continued research and clinical trials are essential to further refine treatment strategies for these hematologic malignancies.

More Related Videos

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma08:31

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma

Published on: September 12, 2025

757
Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells11:08

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

1.7K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
B Cell Activation and Differentiation01:24

B Cell Activation and Differentiation

The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
16.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Primary Lymphoid Organs01:16

Primary Lymphoid Organs

Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
14.6K
Lymphoid Cells and Tissues01:18

Lymphoid Cells and Tissues

Lymphoid cells and tissues are integral to the immune system, which is crucial in maintaining our body's defense against harmful pathogens. They form the building blocks of lymphoid organs, which include the spleen, thymus, and lymph nodes.
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...
2.9K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
6.5K